Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Diabetic foot ulcer
- Focus Registrational; Therapeutic Use
- Sponsors Anterogen
Most Recent Events
- 22 Sep 2025 Status changed from active, no longer recruiting to completed.
- 13 Dec 2024 Planned End Date changed from 30 Sep 2024 to 1 Jun 2025.
- 13 Dec 2024 Status changed from recruiting to active, no longer recruiting.